Meetings

MONTREAL – April 23, 2026 – Findings from the Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS) registry demonstrate that early use of a small heart pump improves outcomes in patients experiencing a severe form of heart failure called cardiogenic shock after suffering from a heart attack and undergoing a stenting procedure. Researchers presented this late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology (CAIC-ACCI) Summit.

MONTREAL – April 23, 2026 – New findings from the Northwell-Shock Registry show that while women with acute myocardial infarction-related cardiogenic shock (AMI-CS) are less likely to receive invasive treatments, clinical decisions are driven by objective markers of illness severity rather than sex. However, the framing for those decisions differs between men and women, suggesting significant differences in how treatment options are discussed with patients and caregivers. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

MONTREAL – April 23, 2026 – New findings from a DETOUR2 substudy show that minimally invasive percutaneous transmural arterial bypass (PTAB) may offer a promising alternative to traditional leg bypass surgery for patients with complex peripheral arterial disease (PAD), even when distal vessel run off is severely limited. Researchers presented the late-breaking data today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions & Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

The Musketeer Foundation Institute of Data Science at the University of Hong Kong (HKU IDS) hosted the Hong Kong Global AI Governance Conference 2026 (HKGAGC 2026) on 10–11 April at the Rayson Huang Theatre, bringing together 38 leading scholars, policymakers, and industry practitioners to examine emerging challenges in artificial intelligence (AI) governance.

A research team from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has demonstrated that robotic total hip replacement has a lower reoperation rate than the conventional technique. The study found a 90-day reoperation rate of only 0.6% with robotic procedures as compared to 2.5% with conventional procedures. Robotic procedures thus promise long-term benefits for patients, enabling them to regain mobility and return to normal life.

An upcoming international online forum will bring together leading researchers to explore how engineered biochar can advance carbon capture and sustainable resource recovery, addressing urgent global climate and environmental challenges.

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

The University of Hong Kong (HKU) announces the launch of the School of Governance and Policy (SGP), a new interdisciplinary hub dedicated to shaping the future of governance and public policy. To mark this milestone, SGP will host its inaugural week from 27 to 29 April 2026, convening global thought leaders, nobel laureate, former heads of state, and leading academics to confront the world’s most urgent regional and transnational challenges.

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.